"Treatment of transthyretin cardiomyopathy with a TTR-specific antisense oligonucleotide (IONIS-TTRRx)." Amyloid, 24(sup1), pp. 134–135
No takes yet. Share an insight, caveat, or question.
Benson et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: